Zacks Small Cap Has Optimistic View of RVPH FY2025 Earnings

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Equities research analysts at Zacks Small Cap boosted their FY2025 earnings per share (EPS) estimates for Reviva Pharmaceuticals in a research note issued to investors on Tuesday, August 19th. Zacks Small Cap analyst J. Vandermosten now anticipates that the company will earn ($0.52) per share for the year, up from their previous forecast of ($0.53). The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.97) per share.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its earnings results on Thursday, August 14th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03.

A number of other analysts also recently weighed in on the stock. Roth Capital reissued a “buy” rating and set a $3.00 target price (down previously from $7.00) on shares of Reviva Pharmaceuticals in a research report on Monday. Citigroup reissued a “buy” rating on shares of Reviva Pharmaceuticals in a research report on Friday, August 15th. Maxim Group decreased their target price on shares of Reviva Pharmaceuticals from $5.00 to $2.00 and set a “buy” rating for the company in a research report on Friday, August 15th. D. Boral Capital reissued a “buy” rating and set a $3.00 target price on shares of Reviva Pharmaceuticals in a research report on Monday. Finally, Wall Street Zen raised shares of Reviva Pharmaceuticals to a “sell” rating in a research report on Saturday, August 16th. One analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $7.17.

Reviva Pharmaceuticals Stock Performance

NASDAQ:RVPH opened at $0.5192 on Thursday. The company has a market capitalization of $24.92 million, a PE ratio of -0.80 and a beta of -0.05. The company has a 50 day simple moving average of $0.49 and a two-hundred day simple moving average of $0.87. Reviva Pharmaceuticals has a fifty-two week low of $0.30 and a fifty-two week high of $4.28.

Institutional Trading of Reviva Pharmaceuticals

Large investors have recently modified their holdings of the stock. Ameriprise Financial Inc. acquired a new stake in shares of Reviva Pharmaceuticals during the 4th quarter worth approximately $84,000. Tower Research Capital LLC TRC grew its position in shares of Reviva Pharmaceuticals by 848.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 26,775 shares of the company’s stock worth $48,000 after buying an additional 23,953 shares during the period. Geode Capital Management LLC grew its position in shares of Reviva Pharmaceuticals by 11.9% during the 4th quarter. Geode Capital Management LLC now owns 311,701 shares of the company’s stock worth $564,000 after buying an additional 33,205 shares during the period. Cornerstone Select Advisors LLC acquired a new stake in shares of Reviva Pharmaceuticals during the 4th quarter worth approximately $32,000. Finally, BluePointe Capital Management LLC grew its position in shares of Reviva Pharmaceuticals by 354.7% during the 1st quarter. BluePointe Capital Management LLC now owns 47,185 shares of the company’s stock worth $45,000 after buying an additional 36,807 shares during the period. Institutional investors and hedge funds own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.